Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Obesity in 2015

Advances in managing obesity

Nature Reviews Endocrinology volume 12, pages 65–66 (2016)Cite this article

Subjects

Successful management of obesity requires integration of pharmaceutical agents and bariatric surgeries with traditional lifestyle modifications. Notable developments for managing obesity in 2015 included the demonstration of weight-beneficial outcomes for liraglutide and empagliflozin, and the first 5-year follow-up of patients with type 2 diabetes mellitus and obesity randomly assigned to receive bariatric surgery or conventional medical therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Successfully treating obesity requires integration of multiple approaches.

References

  1. Moyer, V. A. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 373–378 (2012).

    PubMed  Google Scholar 

  2. Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11–22 (2015).

    Article  Google Scholar 

  3. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  Google Scholar 

  4. Kim, D. D. et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes. Metab. 17, 566–572 (2015).

    Article  CAS  Google Scholar 

  5. Zafgen. Zafgen announces partial clinical hold affecting beloranib trials. [online], (2015).

  6. Mingrone, G. et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386, 964–973 (2015).

    Article  Google Scholar 

  7. Purcell, K. et al. The effect of rate of weight loss on long-term weight management: a randomised controlled trial. Lancet Diabetes Endocrinol. 2, 954–962 (2014).

    Article  Google Scholar 

  8. Johansson, K., Neovius, M. & Hemmingsson, E. Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 99, 14–23 (2014).

    Article  CAS  Google Scholar 

  9. [No authors listed] ReShape and Orbera — two gastric balloon devices for weight loss. Med. Lett. Drugs Ther. 57, 122–123 (2015).

  10. Dietz, W. H. et al. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet 385, 2521–2533 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, 3004, Victoria, Australia

    John B. Dixon

Authors
  1. John B. Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John B. Dixon.

Ethics declarations

Competing interests

J.B.D. has received research funding and consultancy fees from Allergan and Nestlé Australia, and is a member of the Optifast® Medical Advisory Board of Nestlé Australia and the Medical Advisory Board of NovoNordisk. J.B.D. has also been a consultant for Apollo Endosurgery, Bariatric Advantage, mdBriefcase and Nestec, and received honoraria from Covidien, iNova Pharmaceuticals and Merck Sharp & Dohme.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dixon, J. Advances in managing obesity. Nat Rev Endocrinol 12, 65–66 (2016). https://doi.org/10.1038/nrendo.2015.221

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2015.221

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing